文献速递高血压

低剂量三联/四联复方制剂对比单药、常规治疗或安慰剂用于高血压初始管理的疗效与安全性:系统综述与Meta分析

Efficacy and Safety of Low-Dose Triple and Quadruple Combination Pills vs Monotherapy, Usual Care, or Placebo for the Initial Management of Hypertension: A Systematic Review and Meta-analysis.
PubMed 文献 · JAMA Cardiol · 2023-01-01

该系统综述与Meta分析纳入7项随机临床试验共1918例患者,评估含3或4种降压药的低剂量复方制剂(LDC)用于高血压初始管理的疗效与安全性。结果显示,随访4至12周时LDC较单药或常规治疗额外降低收缩压7.4 mmHg,较安慰剂降低18.0 mmHg,且血压达标率更高,但头晕发生率略增,其他不良反应及撤药率无显著差异。

要点

  • LDC较单药或常规治疗额外降低收缩压7.4 mmHg(95%CI 4.3-10.5)
  • LDC组血压<140/90 mmHg达标率66%,单药/常规治疗组46%(RR 1.40)
  • LDC组头晕发生率14% vs 11%(RR 1.28,95%CI 1.00-1.63),撤药率无显著差异

核心结论

  • 含3或4种降压药的低剂量复方制剂是高血压初始或早期管理的有效且耐受性良好的降压治疗选择。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed和Medline自建库至2022年9月,纳入比较含3或4种降压药的LDC与单药、常规治疗或安慰剂的随机临床试验。
  • 共纳入7项试验、1918例患者,平均年龄59岁(范围50-70岁),女性739例(38%),其中4项试验为三联LDC、3项为四联LDC。

主要发现

  • 随访4至12周,LDC较初始单药或常规治疗额外降低收缩压7.4 mmHg(95%CI 4.3-10.5),较安慰剂降低18.0 mmHg(95%CI 15.1-20.8)。
  • LDC组血压<140/90 mmHg达标率66% vs 单药或常规治疗组46%(RR 1.40,95%CI 1.27-1.52),vs 安慰剂组54% vs 18%(RR 3.03,95%CI 1.93-4.77)。
  • 基线是否接受降压治疗的患者亚组间无显著异质性;2项试验显示6至12个月时LDC仍优于单药或常规治疗。
  • LDC与更多头晕相关(14% vs 11%;RR 1.28,95%CI 1.00-1.63),其他不良反应及治疗撤药无显著差异。

临床怎么用

  • 对于高血压初始或早期管理,可考虑使用含3或4种降压药的低剂量复方制剂以更有效降低收缩压并提高血压达标率。
  • 使用LDC时需关注头晕不良反应,但整体耐受性良好,未增加治疗撤药风险。

局限性

  • 纳入试验仅7项、共1918例患者,样本量有限。
  • 随访时间较短,多数结局评估在4至12周,仅2项试验报告6至12个月数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Low-dose combination (LDC) antihypertensives consisting of 3 or 4 blood pressure (BP)-lowering drugs have emerged as a potentially important therapy for the initial management of hypertension. OBJECTIVE: To assess the efficacy and safety of LDC therapies for the management of hypertension. DATA SOURCES: PubMed and Medline were searched from date of inception until September 2022. STUDY SELECTION: Randomized clinical trials comparing LDC consisting of 3 or 4 BP-lowering drugs compared to either monotherapy, usual care, or placebo. DATA EXTRACTION AND SYNTHESIS: Data were extracted by 2 independent authors and synthesized using both random and fixed-effects models using risk ratios (RR) for binary outcomes and mean differences for continuous outcomes. MAIN OUTCOMES AND MEASURES: The primary outcome was mean reduction in systolic BP (SBP) between LDC and monotherapy, usual care, or placebo. Other outcomes of interest included the proportion of patients achieving BP less than 140/90 mm Hg, rates of adverse effects, and treatment withdrawal. RESULTS: Seven trials with a total of 1918 patients (mean [mean range] age, 59 [50-70] years; 739 [38%] female) were included. Four trials involved triple-component LDC and 3 involved quadruple-component LDC. At 4 to 12 weeks follow-up, LDC was associated with a greater mean reduction in SBP than initial monotherapy or usual care (mean reduction, 7.4 mm Hg; 95% CI, 4.3-10.5) and placebo (mean reduction, 18.0 mm Hg; 95% CI, 15.1-20.8). LDC was associated with a higher proportion of participants achieving BP less than 140/90 mm Hg at 4 to 12 weeks compared to both monotherapy or usual care (66% vs 46%; RR, 1.40; 95% CI, 1.27-1.52) and placebo (54% vs 18%; RR, 3.03; 95% CI, 1.93-4.77). There was no significant heterogeneity between trials enrolling patients with and without baseline BP-lowering therapy. Results from 2 trials indicated LDC remained superior to monotherapy or usual care at 6 to 12 months. LDC was associated with more dizziness (14% vs 11%; RR 1.28, 95% CI 1.00-1.63) but no other adverse effects nor treatment withdrawal. CONCLUSIONS AND RELEVANCE: The findings in the study showed that LDCs with 3 or 4 antihypertensives were an effective and well-tolerated BP-lowering treatment option for the initial or early management of hypertension.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Wang N, Rueter P, Atkins E, et al. Efficacy and Safety of Low-Dose Triple and Quadruple Combination Pills vs Monotherapy, Usual Care, or Placebo for the Initial Management of Hypertension: A Systematic Review and Meta-analysis. JAMA Cardiol. 2023. PMID: 37099314. doi:10.1001/jamacardio.2023.0720

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。